S
BCRX icon

SignatureFD’s BioCryst Pharmaceuticals BCRX Stock Holding History

SignatureFD’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.2K Sell
5,524
-142
-3% -$1.28K ﹤0.01% 1814
2026
Q1 		$53.9K Sell
5,666
-94
-2% -$730 ﹤0.01% 1678
2025
Q4 		$44.9K Sell
5,760
-187
-3% -$1.35K ﹤0.01% 1714
2025
Q3 		$45.1K Hold
5,947
– – ﹤0.01% 1692
2025
Q2 		$53.3K Sell
5,947
-235
-4% -$2.19K ﹤0.01% 1550
2025
Q1 		$46.4K Sell
6,182
-507
-8% -$4.09K ﹤0.01% 1613
2024
Q4 		$50.3K Buy
6,689
+384
+6% +$2.92K ﹤0.01% 1582
2024
Q3 		$47.9K Sell
6,305
-293
-4% -$2.23K ﹤0.01% 1597
2024
Q2 		$40.8K Buy
6,598
+5,599
+560% +$30.9K ﹤0.01% 1615
2024
Q1 		$5.08K Sell
999
-684
-41% -$3.85K ﹤0.01% 2536
2023
Q4 		$10.1K Buy
1,683
+910
+118% +$5.27K ﹤0.01% 2254
2023
Q3 		$5.47K Buy
+773
New +$5.55K ﹤0.01% 2456
2023
Q2 		– Sell
-93
Closed -$776 – 3241
2023
Q1 		$776 Buy
+93
New +$895 ﹤0.01% 3038
2022
Q4 		– Sell
-14
Closed – – 3296
2022
Q3 		$0 Buy
+14
New +$180 ﹤0.01% 3113
2022
Q2 		– Sell
-33
Closed -$1K – 3114
2022
Q1 		$1K Buy
+33
New +$529 ﹤0.01% 2947

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SignatureFD's BCRX Position: Q2 2026 in Review

SignatureFD reduced its BioCryst Pharmaceuticals (BCRX) stake by 2.5% in Q2 2026, selling an estimated $1.28K and leaving 5,524 shares worth $55.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

SignatureFD first reported a position in BCRX in Q1 2022 and has held it in 15 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • SignatureFD held 5,524 shares of BioCryst Pharmaceuticals worth $55.2K as of Q2 2026.
  • SignatureFD sold 142 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.28K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1814 holding.
  • SignatureFD first reported a position in BioCryst Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.